Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1678P_PR - The impact of COVID-19 pandemic on cancer care: A global collaborative study


17 Sep 2020


E-Poster Display


COVID-19 and Cancer

Tumour Site


Abdul Rahman Jazieh


Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325


A.R. Jazieh1, H. Akbulut2, G. Curigliano3, A. Rogado4, A.A. Alsharm5, E. Razis6, L.Y.I. Mula-Hussain7, H. Errihani8, A. Khattak9, R.B. De Guzman10, C.C. Mathias11, M.O.F. Alkaiyat1, H. Jradi12, C.D. Rolfo13

Author affiliations

  • 1 Oncology Dept., King Abdulaziz Medical City-Riyadh, 11426 - Riyadh/SA
  • 2 Department Of Medical Oncology, Ankara University School of Medicine, 0000 - Ankara/TR
  • 3 Early Drug Development for Innovative Therapies Division, University Of Milano, Istituto Europeo di Oncologia, 20141 - Milan/IT
  • 4 Executive Director, Eco Foundation, Fundacion ECO, 0000 - Madrid/ES
  • 5 Oncology Dept., King Fahad Medical City, 0000 - Riyadh/SA
  • 6 Oncology Dept., Hygeia Hospital, 0000 - Athens/GR
  • 7 Radiation Oncology Department, University of Alberta Cross Cancer Institute, T6G 1Z2 - Edmonton/CA
  • 8 Oncology, National institut of oncology, 10104 - Rabat/MA
  • 9 Oncology, Fiona Stanley Hospital, 6961 - Perth/AU
  • 10 Oncology, Manila Central University - FDTMF Hospital, 0000 - Caloocan/PH
  • 11 Oncology, NOB Oncoclínicas, 0000 - Salvador/BR
  • 12 Public Health, King Saud bin Abdulaziz University for Health Sciences, 0000 - Riyadh/SA
  • 13 Thoracic Oncology & Early Clincial Trials, Medicine Department, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, MD 21201 - Baltimore/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1678P_PR


COVID-19 pandemic impacted healthcare systems globally and resulted in the interruption of usual care in many healthcare facilities exposing vulnerable cancer patients to significant risks. Our study aimed to evaluate the impact of this pandemic on cancer care worldwide.


We conducted a cross-sectional study using validated electronic questionnaire of 51 items via SurveyMonkey©. The tool was distributed to leaders in oncology centers worldwide. The questionnaire obtained information on the capacity and services offered at these centers, magnitude of interruption of care, reasons for interruption, challenges faced, interventions implemented, and the estimation of patient harm during the pandemic.


356 centers from 54 countries across six continents participated between April 21 and May 8, 2020. These centers serve about 700,000 new cancer patients a year. Most of them (88%) reported facing challenges in providing care during the pandemic. 54% and 45% of centers reported cases of COVID-19 infection among their patients and staff, respectively. Although 51% reduced services as part of a preemptive strategy, other common reasons included overwhelmed system (20%), lack of personal protective equipment (19%), staff shortage (18%), and restricted access to medications (9.7%). Missing at least one cycle of therapy by more than 10% of patients was reported in 46% of the centers. Most centers implemented virtual clinics (83.6%) and virtual tumor boards (93%) and participants believed these will persist beyond the pandemic (55.5% and 60%, respectively). Centers performed routine tests in laboratories near patients’ homes (76%) and shipped medications to patients (68.6%). Participants reported patients’ exposure to harm from interruption of cancer-specific care (36.5%) and non-cancer related care (39%) with some centers estimating up to 80% of their patients exposed to some harm. Only 16% of the centers reported services are back to baseline at the time of completing the survey.


The detrimental impact of COVID-19 pandemic on cancer care is widespread with varying magnitude among centers worldwide. Further research to assess this impact at the patient level is required. A “new normal” of cancer care emerged with emphasis on telehealth and care delivery closer to home.

Clinical trial identification

Editorial acknowledgement

On behalf the International Research Network on COVID-19 Impact on Cancer Care (IRN-CICC)

Legal entity responsible for the study

The authors.


Has not received any funding.


A.R. Jazieh: Research grant/Funding (self): MSD. C.D. Rolfo: Speaker Bureau/Expert testimony: AstraZeneca; Advisory/Consultancy: Inivata; Archer; MD Serono; Mylan; Oncompass; Honoraria (self): Elsevier. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.